I listened to the presentation. Novadaq is really increasing the number of utilizations of all of its products. They are hoping to achieve standard of care with their products and so they will be doing phase III type trials. Pinpoint in colorectal surgery is showing no leaks and so some surgeons are saying that ethically they should not do clinical trials but novadaq has decided to go ahead and do a phase III trial and will start recruiting in q1 of 2014 I think the sentinel node biopsies is another area where it will likely achieve standard of care. If the endometriosis trials are as promising as suggested, this will also likely become standard of care. Finally with wound care and vascular surgery, being able to evaluate perfusion is huge in deciding further treatment options. They are also hoping to get their systems to 100 hospitals by the end of next year. Right now they are focussing on teaching hospitals.
Reducing complications and risks of complications is what Medicare and hospitals and of course surgeons are aiming for.
It is frustrating to see the stock price dwindle but I really think this company has huge potential and I think shareholders are going to be handsomely rewarded.
Nice summary. I also listened to the presentation and want to pick up on one of your comments on colorectal cancer. I think they might have let the cat out of the bag on the Pilar study. Maybe it was wishful thinking on my part, but I got the impression from comments made that the full Pilar study is going to show no leaks and it will be directly attributable to procedure changes made during some of the surgeries due to our equipment.
Bear in mind, the original gameplan was to have Arum present the results of Pilar at a conference at this time. This was then changed to having the results presented in a reputable medical Journal in the first quarter. Was this change the result of no leaks???